About Halozyme

Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment (TME). Current research is evaluating if degradation of potential barriers within the desmoplastic TMEs of certain difficult-to-treat cancers may help make existing treatments and immune cells more effective by increasing tumoral access.

Learn more about Halozyme’s research →